These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30530703)

  • 1. Anagrelide for Gastrointestinal Stromal Tumor.
    Pulkka OP; Gebreyohannes YK; Wozniak A; Mpindi JP; Tynninen O; Icay K; Cervera A; Keskitalo S; Murumägi A; Kulesskiy E; Laaksonen M; Wennerberg K; Varjosalo M; Laakkonen P; Lehtonen R; Hautaniemi S; Kallioniemi O; Schöffski P; Sihto H; Joensuu H
    Clin Cancer Res; 2019 Mar; 25(5):1676-1687. PubMed ID: 30530703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors.
    Takaki EO; Kiyono K; Obuchi Y; Yamauchi T; Watanabe T; Matsumoto H; Karimine M; Kuniyoshi Y; Nishikori S; Yokoyama F; Nishimori H; Nabeshima H; Nakamura K
    Clin Cancer Res; 2024 Aug; 30(16):3603-3621. PubMed ID: 38864850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase 3A: a new player in development of interstitial cells of Cajal and a prospective target in gastrointestinal stromal tumors (GIST).
    Vandenberghe P; Hagué P; Hockman SC; Manganiello VC; Demetter P; Erneux C; Vanderwinden JM
    Oncotarget; 2017 Jun; 8(25):41026-41043. PubMed ID: 28454120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
    Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.
    Li F; Huynh H; Li X; Ruddy DA; Wang Y; Ong R; Chow P; Qiu S; Tam A; Rakiec DP; Schlegel R; Monahan JE; Huang A
    Cancer Discov; 2015 Apr; 5(4):438-51. PubMed ID: 25673643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting tumor cells based on Phosphodiesterase 3A expression.
    Nazir M; Senkowski W; Nyberg F; Blom K; Edqvist PH; Jarvius M; Andersson C; Gustafsson MG; Nygren P; Larsson R; Fryknäs M
    Exp Cell Res; 2017 Dec; 361(2):308-315. PubMed ID: 29107068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors.
    Lu X; Pang Y; Cao H; Liu X; Tu L; Shen Y; Jia X; Lee JC; Wang Y
    Cancer Res; 2021 May; 81(9):2481-2494. PubMed ID: 33727226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST).
    De Sutter L; Wozniak A; Verreet J; Vanleeuw U; De Cock L; Linde N; Drechsler C; Esdar C; Sciot R; Schöffski P
    Clin Cancer Res; 2023 Aug; 29(15):2859-2868. PubMed ID: 37223931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment.
    Ye S; Sharipova D; Kozinova M; Klug L; D'Souza J; Belinsky MG; Johnson KJ; Einarson MB; Devarajan K; Zhou Y; Litwin S; Heinrich MC; DeMatteo R; von Mehren M; Duncan JS; Rink L
    JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33320833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
    Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
    Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
    Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells.
    Sako H; Fukuda K; Saikawa Y; Nakamura R; Takahashi T; Wada N; Kawakubo H; Takeuchi H; Ohmori T; Kitagawa Y
    PLoS One; 2014; 9(9):e107613. PubMed ID: 25221952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
    Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
    Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
    Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
    Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of novel fusion genes in human GIST cell lines derived from imatinib-resistant GIST patients: A therapeutic potential of fusion gene.
    Cho WC; Shin YK; Na YS; Ryu MH; Ku JL; Kang YK
    Biochem Biophys Res Commun; 2020 Aug; 529(3):699-706. PubMed ID: 32736695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model.
    Floris G; Debiec-Rychter M; Sciot R; Stefan C; Fieuws S; Machiels K; Atadja P; Wozniak A; Faa G; Schöffski P
    Clin Cancer Res; 2009 Jun; 15(12):4066-76. PubMed ID: 19509176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
    Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
    Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.